Search Within

Glenn Heller

Formats
  1. Journal Article (267)
  2. Meeting Abstract (123)
  3. Conference Paper (9)
Groups
  1. Biostatistics Service (399)
  2. Epidemiology and Biostatistics (399)
  3. Department of Medicine (299)
  4. GSK Faculty (192)
  5. Center for Hematologic Malignancies (162)
  6. Pediatrics, Department of (158)

More Groups

People
  1. Howard Scher (89)
  2. Richard O'Reilly (75)
  3. Nancy Kernan (59)
  4. Michael Morris (54)
  5. James Young (52)
  6. Marcel Van Den Brink (47)

More People

Years
  1. 2025 (3)
  2. 2024 (6)
  3. 2023 (9)
  4. 2022 (9)
  5. 2021 (9)
  6. 2020 (12)

More Years

Publications
  1. Journal of Clinical Oncology (82)
  2. Blood (69)
  3. Biology of Blood and Marrow Transplantation (32)
  4. Clinical Cancer Research (24)
  5. Bone Marrow Transplantation (13)
  6. Cancer (13)

More Publications

Publishers
  1. American Society of Clinical Oncology (84)
  2. American Society of Hematology (70)
  3. Elsevier Inc. (41)
  4. American Association for Cancer Research (40)
  5. Nature Publishing Group (26)
  6. Elsevier Science, Inc. (24)

More Publishers

Results (399)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Precision diagnostics in prostate cancer treatment (PREDICT): A phase 2 multi-arm biomarker-based study (Alliance A032102)
    Meeting Abstract

    McKay, R. R.; Heller, G.; Zhao, S.; Wulff-Burchfield, E. M.; Shah, D.; Tan, A.; Galsky, M. D.; Rosenberg, J. E.; Beltran, H.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • A novel predictive model using changes in clinical and serum biomarkers and automated quantitative imaging for mCRPC patients treated with AR-directed therapy
    Meeting Abstract

    Morris, M. J.; Flynn, J.; Zhao, B.; Anand, A.; Sjöstrand, K.; Larson, S. M.; Scher, H. I.; Regazzi, A. M.; Borzillo, G. V.; Park, A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Measuring the impact of new risk factors within survival models
    Journal Article

    Heller, G.; Devlin, S. M.
    Journal of the Royal Statistical Society Series C - Applied Statistics (2025)

    Fulltext@MSK | Save
  • Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients
    Meeting Abstract

    Knezevic, A.; Heller, G.; Sjöstrand, K.; Anand, A.; Borzillo, G.; Larson, S.; Morris, M. J.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Clonal hematopoiesis and clinical outcomes in metastatic castration-resistant prostate cancer patients given androgen receptor pathway inhibitors (Alliance A031201)
    Journal Article

    Jensen, J. L.; Bobek, O.; Chan, I. C. C.; Miller, B. C.; Hillman, D. W.; Heller, G.; Druley, T.; Armstrong, A. J.; Morris, M. J.; Milowsky, M. I.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • A phase I/II study of valemetostat (DS-3201b), an EZH1/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer
    Journal Article

    Choudhury, N. J.; Lai, W. V.; Makhnin, A.; Heller, G.; Eng, J.; Li, B.; Preeshagul, I.; Santini, F. C.; Offin, M.; Ng, K.; more...
    Clinical Cancer Research (2024)

    Fulltext@MSK | Save
  • A phase 2 trial of ADT interruption in patients responding exceptionally to AR-pathway inhibitor in metastatic hormone-sensitive prostate cancer (A-DREAM/Alliance A032101)
    Meeting Abstract

    Choudhury, A. D.; Heller, G.; Reimers, M. A.; Laccetti, A. L.; Smieliauskas, F.; Ravi, P.; Dooley, K.; Mazza, G. L.; Gartrell, B. A.; Steen, P. D.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease
    Meeting Abstract

    Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • PRESTO: A phase III, open-label study of intensification of androgen blockade in patients with high-risk biochemically relapsed castration-sensitive prostate cancer (AFT-19)
    Journal Article

    Aggarwal, R.; Heller, G.; Hillman, D. W.; Xiao, H.; Picus, J.; Taplin, M. E.; Dorff, T.; Appleman, L.; Weckstein, D.; Patnaik, A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Lorlatinib tolerability and association with clinical outcomes in patients with advanced ALK- or ROS1-rearranged NSCLC: A brief report
    Journal Article

    Thummalapalli, R.; Choudhury, N. J.; Ehrich, F.; Beardslee, T.; Brazel, D.; Zhang, S. S.; Merchant, S.; Chen, M. F.; Heller, G.; Ramalingam, S. S.; more...
    JTO Clinical and Research Reports (2023)

    Fulltext@MSK | Save